Journal Article

Hepatocellular carcinoma immune prognosis score predicts the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors

Wang, Peng, Zhao, Haoran, Guo, Zuoming, Liu, Chunxun, Qu, Zhaowei, Zhang, Rujia

2023

Overview

Objective The predictive biomarkers of immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC) still need to be further explored. This study aims to establish a new immune prognosis biomarker to predict the clinical outcomes of hepatocellular carcinoma patients receiving immune checkpoint inhibitors. Methods The subjects of this study were 151 HCC patients receiving ICIs at Harbin Medical University Cancer Hospital from January 2018 to December 2021. This study collected a wide range of blood parameters from patients before treatment and used Cox’s regression analysis to identify independent prognostic factors in blood parameters, as well as their β coefficient. The hepatocellular carcinoma immune prognosis score (HCIPS) was established through Lasso regression analysis and COX multivariate analysis. The cut-off value of HCIPS was calculated from the receiver operating characteristic (ROC) curve. Finally, the prognostic value of HCIPS was validated through survival analysis, stratified analyses, and nomograms. Results HCIPS was composed of albumin (ALB) and thrombin time (TT), with a cut-off value of 0.64. There were 56 patients with HCIPS < 0.64 and 95 patients with HCIPS ≥ 0.64, patients with low HCIPS were significantly related to shorter progression-free survival (PFS) (13.10 months vs. 1.63 months, P  < 0.001) and overall survival (OS) (14.83 months vs. 25.43 months, P  < 0.001). HCIPS has also been found to be an independent prognostic factor in this study. In addition, the stratified analysis found a significant correlation between low HCIPS and shorter OS in patients with tumor size ≥ 5 cm ( P of interaction = 0.032). The C-index and 95% CI of the nomograms for PFS and OS were 0.730 (0.680–0.779) and 0.758 (0.711–0.804), respectively. Conclusions As a new score established based on HCC patients receiving ICIs, HCIPS was significantly correlated with clinical outcomes in patients with ICIs and might serve as a new biomarker to predict HCC patients who cloud benefit from ICIs.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Analysis / Antigens / Biological markers / Biomarkers / Biomedical and Life Sciences / Biomedicine / Blood / Cancer / Cancer Research / Cancer therapies / Care and treatment / Chemotherapy / Clinical outcomes / Clinical trials / Correlation analysis / Development and progression / Health Promotion and Disease Prevention / Hepatectomy / Hepatocellular carcinoma / Hepatoma / Immune checkpoint inhibitors / Inflammation / Liver cancer / Lymphocytes / Medical colleges / Medical prognosis / Medicine/Public Health / Multivariate analysis / Neutrophils / Non-invasive biomarkers / Oncology / Oncology, Experimental / Patient outcomes / Patients / Prognosis / Prognosis score / Regression analysis / Response rates / Statistical analysis / Surgery / Surgical Oncology / Survival / Thrombin / Tumors